Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Jul 7

PMID 31277414

Citations 40

Authors

Stephanie Hunter

Braydon Nault

Kingsley Chukwunonso Ugwuagbo

Sujit Maiti

Mousumi Majumder

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are small endogenously produced RNAs, which regulate growth and development, and oncogenic miRNA regulate tumor growth and metastasis. Tumour-associated angiogenesis and lymphangiogenesis are processes involving the release of growth factors from tumour cells into the microenvioronemnt to communicate with endothelial cells to induce vascular propagation. Here, we examined the roles of cyclo-oxygenase (COX)-2 induced miR526b and miR655 in tumour-associated angiogenesis and lymphangiogenesis. Ectopic overexpression of miR526b and miR655 in poorly metastatic estrogen receptor (ER) positive MCF7 breast cancer cells resulted in upregulation of angiogenesis and lymphangiogenesis markers vascular endothelial growth factor A (VEGFA); VEGFC; VEGFD; COX-2; lymphatic vessel endothelial hyaluronan receptor-1 (LYVE1); and receptors , , and . Further, miRNA-high cell free conditioned media promoted migration and tube formation by human umbilical vein endothelial cells (HUVECs), and upregulated and expression, showing paracrine stimulation of miRNA in the tumor microenvironment. The miRNA-induced migration and tube formation phenotypes were abrogated with antagonist or PI3K/Akt inhibitor treatments, confirming the involvement of the and PI3K/Akt pathway. Tumour supressor gene was found to be downregulated in miRNA high cells, confirming that it is a target of both miRNAs. inhibits hypoxia-inducible factor-1 (HIF1α) and the PI3K/Akt pathway, and loss of regulation of these pathways through results in upregulation of VEGF expression. Moreover, in breast tumors, angiogenesis marker and lymphangiogenesis marker expression was found to be significantly higher compared with non-adjacent control, and expression of miR526b and miR655 was positively correlated with and expression in breast tumour samples. These findings further strengthen the role of miRNAs as breast cancer biomarkers and as a potential therapeutic target to abrogate miRNA-induced angiogenesis and lymphangiogenesis in breast cancer.

Citing Articles

Inhibition of Lymphangiogenesis: A Protective Role of microRNA 146a-5p in Breast Cancer.

Liang W, Wang H, Fu B, Song Y, Zhang Z, Liu X Breast J. 2025; 2024:7813083.

PMID: 39742358 PMC: 11357816. DOI: 10.1155/2024/7813083.

Unraveling non-coding RNAs in breast cancer: mechanistic insights and therapeutic potential.

Shaikh M, Doshi G Med Oncol. 2024; 42(1):37.

PMID: 39730979 DOI: 10.1007/s12032-024-02589-x.

A Prospective Tumour Marker for Breast Cancer: YWHAB and Its Role in Promoting Oncogenic Phenotypes.

Gopaul V, Winstone L, Gatien B, Nault B, Maiti S, Opperman R Breast Cancer (Dove Med Press). 2024; 16:935-956.

PMID: 39703345 PMC: 11656333. DOI: 10.2147/BCTT.S479384.

The role of cancer-associated fibroblasts and exosomal miRNAs-mediated intercellular communication in the tumor microenvironment and the biology of carcinogenesis: a systematic review.

Nedaeinia R, Najafgholian S, Salehi R, Goli M, Ranjbar M, Nickho H Cell Death Discov. 2024; 10(1):380.

PMID: 39187523 PMC: 11347635. DOI: 10.1038/s41420-024-02146-5.

Research progress in tumor angiogenesis and drug resistance in breast cancer.

Mou J, Li C, Zheng Q, Meng X, Tang H Cancer Biol Med. 2024; 21(7).

PMID: 38940663 PMC: 11271221. DOI: 10.20892/j.issn.2095-3941.2023.0515.

References

Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C . Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002; 62(3):632-5. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Weigand M, Hantel P, Kreienberg R, Waltenberger J . Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis. 2005; 8(3):197-204. DOI: 10.1007/s10456-005-9010-0. View

Timoshenko A, Chakraborty C, Wagner G, Lala P . COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer. 2006; 94(8):1154-63. PMC: 2361247. DOI: 10.1038/sj.bjc.6603067. View

Hirota K, Semenza G . Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006; 59(1):15-26. DOI: 10.1016/j.critrevonc.2005.12.003. View

Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R . Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem. 2007; 282(23):16959-68. DOI: 10.1074/jbc.M701214200. View

Otrock Z, Mahfouz R, Makarem J, Shamseddine A . Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis. 2007; 39(2):212-20. DOI: 10.1016/j.bcmd.2007.04.001. View

Singh-Ranger G, Salhab M, Mokbel K . The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat. 2007; 109(2):189-98. DOI: 10.1007/s10549-007-9641-5. View

Howe L . Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007; 9(4):210. PMC: 2206709. DOI: 10.1186/bcr1678. View

10.

Urbich C, Kuehbacher A, Dimmeler S . Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008; 79(4):581-8. DOI: 10.1093/cvr/cvn156. View

11.

Ran S, Volk L, Hall K, Flister M . Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology. 2009; 17(4):229-51. PMC: 2891887. DOI: 10.1016/j.pathophys.2009.11.003. View

12.

Cascio S, DAndrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V . miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 2010; 224(1):242-9. DOI: 10.1002/jcp.22126. View

13.

Weis S, Cheresh D . Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11):1359-70. DOI: 10.1038/nm.2537. View

14.

Xin X, Majumder M, Girish G, Mohindra V, Maruyama T, Lala P . Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest. 2012; 92(8):1115-28. DOI: 10.1038/labinvest.2012.90. View

15.

Sasahira T, Kurihara M, Bhawal U, Ueda N, Shimomoto T, Yamamoto K . Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer. 2012; 107(4):700-6. PMC: 3419968. DOI: 10.1038/bjc.2012.330. View

16.

Shibuya M . Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2012; 2(12):1097-105. PMC: 3411125. DOI: 10.1177/1947601911423031. View

17.

Perrot-Applanat M, Di Benedetto M . Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr. 2012; 6(6):547-53. PMC: 3547902. DOI: 10.4161/cam.23332. View

18.

Singh R, Mo Y . Role of microRNAs in breast cancer. Cancer Biol Ther. 2013; 14(3):201-12. PMC: 3595302. DOI: 10.4161/cbt.23296. View

19.

Kong W, He L, Richards E, Challa S, Xu C, Permuth-Wey J . Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2013; 33(6):679-89. PMC: 3925335. DOI: 10.1038/onc.2012.636. View

20.

Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo M . Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition. PLoS One. 2013; 8(6):e65217. PMC: 3679135. DOI: 10.1371/journal.pone.0065217. View